What is established

• It has documented antitumour and immunomodulatory activity in mouse tumour models. An ethanolic extract reduced DLA-induced solid tumour growth and boosted immune parameters. A follow-up study looked at cell-mediated immunity and cytotoxic T-lymphocyte generation in normal and tumour-bearing mice. An earlier DLA solid tumour study also reported tumour reduction.
• A phytochemistry and pharmacology review lists flavonoids (kaempferol and quercetin derivatives), alkaloids, and phenolics as the main constituents. These are the usual suspects for antioxidant, anti-inflammatory and anti-angiogenic effects.
• A preprint-level report describes anti-angiogenic activity of A. lanata flowers. I haven't verified it.
• Toxicology data exist for the aqueous whole-plant extract.

• Metformin activates AMPK, partly via LKB1. This inhibits mTOR and lowers mitochondrial complex I activity. Harrison's also describes metformin as inhibiting gluconeogenesis and possibly acting directly on tumour cells through AMPK (Harrison's Principles of Internal Medicine 22E, Cancer Metabolism).
• Preclinical work links metformin to lower HIF-1α and VEGF. One example is suppression of tumour angiogenesis via the HER2/HIF-1α/VEGF axis. Reviews cover metformin and angiogenesis.
• The effect is not uniform. One study reported paradoxic effects on endothelial cells, and another found therapeutic doses had no effect on angiogenesis in sera from pregnancies. Dose and context matter.

How a study with this title is usually designed

What to check when reading the paper

1. Synergy needs a formal test. Seeing the combination do better than either agent alone doesn't prove synergy. Look for isobologram or combination index analysis, or a factorial design.
2. Extract standardisation. The paper should state the plant part, solvent, yield, and phytochemical fingerprint (HPLC or LC-MS). Without these, the results can't be reproduced.
3. Metformin dose translation. Mouse doses are often far above human exposure. "Low-dose" should be checked against human-equivalent dosing (body surface area scaling).
4. CAM limitations. The CAM is an embryonic, immunodeficient-like model. Non-specific irritation or toxicity can mimic anti-angiogenesis, so the vehicle control, disc effects and embryo mortality matter.
5. Mechanism claims. Statements about AMPK, mTOR, VEGF or HIF-1α should be backed by measurements such as Western blot or ELISA, not inferred.
6. EAC solid tumour limits. This is a murine, transplantable, non-human tumour. Results don't translate directly to human cancers, and group sizes are often small.

Recent evidence on metformin and cancer in humans

The key problem with Cissus + phenytoin

• Phenytoin is pro-angiogenic and pro-healing. In rats, VEGF and bFGF were linked to its wound-healing effect. A case report describes angiogenesis and faster ulcer healing.
• If the CAM or tumour endpoints are anti-angiogenic, phenytoin would work against the plant. That is a hard hypothesis to defend.
• Cissus quadrangularis is better known for fracture healing, which suggests a bone or wound study. But it also inhibited angiogenesis in an arthritis model. So its direction of effect depends on context, and that muddies the rationale.
• The 4 to 8 weeks of dosing also adds animal-house cost and ethics burden.

The case for valproate

• Valproate inhibits histone deacetylase (Goodman & Gilman's The Pharmacological Basis of Therapeutics, Mechanism of Action). HDAC inhibition is the proposed route to its antitumour effects.
• Published studies show valproate inhibits angiogenesis in glioma, prostate cancer xenografts and leukaemia xenografts.
• It has already been tested in the CAM model, with lung tumours responding differently to sodium valproate. So the assay is validated for this drug.
• Valproate is cheap, and the CAM assay takes days. An EAC solid tumour study runs about 2 to 3 weeks.
• One risk is that valproate is embryotoxic. In ovo, you need embryo viability and mortality controls, or toxicity could pass for anti-angiogenesis.

Fixing the plant name

• Vallarai is Centella asiatica. Aerva lanata is a different plant (Polpala or Sirupeelai).
• Pick one and keep it consistent. Your title uses Aerva lanata, which already has EAC and DLA solid tumour data, so a prior exists.
• Centella is a weaker fit for an anti-tumour design. It shows anti-angiogenic activity in network pharmacology work, but it is also widely reported to promote wound healing.

Ratings (out of 10)

Recommendation

1. For the CAM + EAC design, pick Aerva lanata with either valproate or metformin. They score about the same. Metformin is easier to justify as "low dose" and as repurposing. Valproate has the cleaner anti-angiogenic precedent.
2. If you want a quick, cheap project, use a 2x2 design: plant alone, drug alone, combination, and vehicle. Add a combination index analysis, because that is what supports a synergy claim.
3. Only choose Cissus + phenytoin if you redefine the endpoints around bone or wound repair, and accept the longer dosing.